ONCY

Oncolytics Biotech Inc. (ONCY) is a Calgary-based clinical-stage biopharmaceutical company pioneering the development of oncolytic virus therapies aimed at treating various cancers. Its lead asset, pelareorep, employs a distinctive mechanism that targets cancer cells while enhancing the immune response, thus presenting a transformative approach to oncology treatment. With a robust pipeline supported by several ongoing clinical trials, Oncolytics is committed to advancing cutting-edge cancer therapies that aim to improve patient outcomes. The company's strong research capabilities and strategic partnerships further bolster its competitive edge in the dynamic oncology sector.